Concepedia

R. Angelo de Claro

RA

25

Publications

1.5K

Citations

19

H-Index

2004

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Amgen (United States)

University of Washington

Johns Hopkins University

R. Angelo de Claro is an author at Center for Drug Evaluation and Research specializing in medicine, clinical trials, and oncology.

ORCID

Top concepts

Publications per year

2004–2024

25

Publications

25

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro et al. · Clinical Cancer Research · 2018 · 220 citations

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 207 citations

, , +12

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang et al. · The Oncologist · 2017 · 189 citations · Full text

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun et al. · Clinical Cancer Research · 2015 · 156 citations

, , +18

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Dianne Pulte, Kelly J. Norsworthy, Yaping Wang et al. · Clinical Cancer Research · 2021 · 75 citations · Full text

Rows per page

1–5 of 25